Literature DB >> 17257501

Induction of tumor cell apoptosis via Fas/DR5.

Wenzhu Li1, Shengyu Wang, Caixia Chen, Guohong Zhuang.   

Abstract

The apoptosis inducing effects on tumor cell lines MGC803, BEL7402 and HL60 by Fas ligand and anti-human DR5 monoclonal antibodies (anti-DR5 mAb) and the underlying mechanism was studied. Fas/DR5 mRNA was detected by RT-PCR. Cytotoxicity exerted by FasL/anti-DR5 mAb on tumor cell lines was measured by MTT assay and the induced apoptosis was determined by agarose gel electrophoresis. Flow cytometry was employed to analyze the mode of cell death. The mRNA expression of DR5 in MGC803 and BEL7402 cells after giving anti-DR5 mAb was up-regulated compared with control group, while it was down-regulated in HL60 cells in the same condition. The mRNA expression of Fas in HL60 was higher after giving FasL compared with control group, while it was lower in MGC803 and BEL7402. MGC803 and BEL7402 were sensitive to anti-DR5 mAb but partially to FasL, and HL60 was sensitive to FasL but less sensitive to anti-DR5 mAb. Apoptosis induced by Fas ligand and anti-DR5 mAb vary among tumor cell lines. The underlying mechanism may be relevant to Fas/DR5 mRNA expression, which was presented as the release of caspase-8 and Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17257501

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  2 in total

1.  Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells.

Authors:  Jia-hua Zhang; Li-qiong Liu; Yan-li He; Wei-jia Kong; Shi-ang Huang
Journal:  Acta Pharmacol Sin       Date:  2010-06-28       Impact factor: 6.150

2.  IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells.

Authors:  Rosario Amato; Miranda Menniti; Valter Agosti; Rosalia Boito; Nicola Costa; Heather M Bond; Vito Barbieri; Pierosandro Tagliaferri; Salvatore Venuta; Nicola Perrotti
Journal:  J Mol Med (Berl)       Date:  2007-06-15       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.